Major depressive disorder in hepatitis C: An open-label trial of escitalopram

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 7, Issue 5, 2005, Pages 225-230

  Gleason, Ondria C ^a   Yates, William R ^a   Philipsen, Michelle A ^a  

^a University of Oklahoma Tulsa College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESCITALOPRAM; INTERFERON;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; HEPATITIS C; HUMAN; LIVER FUNCTION TEST; LIVER TOXICITY; MAJOR DEPRESSION; MALE; QUALITY OF LIFE; RATING SCALE;

EID: 28244480740     PISSN: 15235998     EISSN: None     Source Type: Journal    
DOI: 10.4088/pcc.v07n0503     Document Type: Article

References (43)

1. World Health Organization. Available at: http://www.who.int/csr/disease/ hepatitis/en/. Accessed Aug 29, 2005
2. Alter MJ, Kruszon-Moran D, Nainain OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-562
3. Everhart JE, Wei Y, Eng H, et al. Recurrent and new hepatitis C virus infection after liver transplantation. Hepatology 1999;4:1220-1226
4. El-Serag HB, Kunik M, Richardson P, et al. Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology 2002;123:476-482
5. Dwight MM, Kowdley KV, Russo JE, et al. Depression, fatigue, and functional disability in patients with chronic hepatitis C. J Psychosom Res 2000;49:311-317
6. Lee DH, Jamal H, Regenstein FG, et al. Morbidity of chronic hepatitis C as seen in a tertiary care medical center. Dig Dis Sci 1997;42:186-191
7. Gohier B, Goeb JL, Rannou-Dubas K, et al. Hepatitis C, alpha interferon, anxiety and depression disorders: a prospective study of 71 patients. World J Biol Psychiatry 2003;4:115-118
8. Kraus MR, Schafer HC, Scheurlen M, et al. Emotional state, coping styles, and somatic variables in patients with chronic hepatitis C. Psychosomatics 2000;41:377-384
9. Hunt CM, Dominitz JA, Philips Bute B, et al. Effect of interferon-alfa treatment of chronic hepatitis C on health-related quality of life. Dig Dis Sci 1997;42:2482-2486
10. Yovtcheva SP, Rifai MA, Moles JK, et al. Psychiatric comorbidity among hepatitis C-positive patients. Psychosomatics 2001;42:411-415
11. Lehman CL, Cheung RC. Depression, anxiety, post-traumatic stress, and alcohol-related problems among veterans with chronic hepatitis C. Am J Gastroenterol 2002;97:2640-2646
12. Kessler RC, Berglund P, Demler O. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:593-602
13. Zdilar D, Franco-Bronson K, Buchler N, et al. Hepatitis C, Interferon alfa, and depression. Hepatology 2000;31:1207-1211
14. Dieperink E, Ho SB, Thuras P, et al. A prospective study of neuropsychiatric symptoms associated with interferon-alfa-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 2003;44:104-112
15. Hauser P, Khosla J, Aurora H, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002;7:942-947
16. Horikawa N, Yamazaki T, Izumi N. Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study. Gen Hosp Psychiatry 2003;25:34-38
17. Kraus MR, Schäfer A, Faller H, et al. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry 2003;64:708-714
18. Pariante C, Orru MG, Baita A, et al. Treatment with interferon-alfa in patients with chronic hepatitis and mood or anxiety disorders [letter]. Lancet 1999;354:131-132
19. Rowan PJ, Tabasi S, Abdul-Latif M, et al. Psychosocial factors are the most common contraindications for antiviral therapy at initial evaluation in veterans with chronic hepatitis C. J Clin Gastroenterol 2004;38: 530-534
20. Dieperink E, Willenbring E, Ho SB. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry 2000;157:867-876
21. Falck-Ytter Y, Kale H, Mullen KD, et al. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002;136:288-292
22. Loftis JM, Hauser P. Safety of the treatment of interferon-alpha-induced depression [letter]. Psychosomatics 2003;44:524-526
23. Weinrieb RM, Auriacombe M, Lynch KG, et al. A critical review of selective serotonin reuptake inhibitor-associated bleeding: balancing the risk of treating hepatitis C-infected patients. J Clin Psychiatry 2003;64: 1502-1510
24. Hejny C, Sternberg P, Lawson DH, et al. Retinopathy associated with high-dose interferon alfa-2b therapy. Am J Ophthalmol 2001;131: 782-787
25. Ozcanli T, Unsalver B, Ozdemir S, et al. Sertraline- and mirtazapine-induced severe neutropenia [letter]. Am J Psychiatry 2005;162:1386
26. Choi S. Nefazodone (Serzone) withdrawn because of hepatotoxicity. CMAJ 2003;169:1187
27. Gleason OC, Yates WR. Five cases of interferon-alfa-induced depression treated with antidepressant therapy. Psychosomatics 1999;40:510-512
28. Levenson JL, Fallon HJ. Fluoxetine treatment of depression caused by interferon-alfa. Am J Gastroenterol 1993;88:760-761
29. Schramm TM, Lawford BR, Macdonald GA, et al. Sertraline treatment of interferon-alfa-induced depressive disorder. Med J Aust 2000;173:359-361
30. Kraus MR, Schäfer A, Faller H, et al. Paroxetine for the treatment of interferon-alfa-induced depression in chronic hepatitis C. Aliment Pharmacol Ther 2002;16:1091-1099
31. Goldman LS. Successful treatment of interferon alfa-induced mood disorder with nortriptyline [letter]. Psychosomatics 1994;35:412-113
32. Gleason OC, Yates WR, Isbell MD, et al. An open-label trial of citalopram for major depression in patients with hepatitis C. J Clin Psychiatry 2002;63:194-198
33. Lopez-Torres E. Hepatotoxicity related to citalopram [letter]. Am J Psychiatry 2004;161:923-924
34. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198
35. Berg R, Franzen M, Wedding D. Screening for Brain Impairment: A Manual for Mental Health Practice. New York, NY: Springer Publishing Company, Inc; 1987
36. Sheehan DV, Lecrubier Y, Harnett-Sheehan K, et al. The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview. J Clin Psychiatry 1998;59(suppl 20):22-33
37. Hamilton M. Hamilton Depression Scale. In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:179-192
38. Derogatis LR. Symptom Checklist-90-Revised (SCL-90-R). In: Task Force for the Handbook of Psychiatric Measures. Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association; 2000: 81-84
39. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36), 1: conceptual framework and item selection. Med Care 1992; 30:473-483
40. National Institute of Mental Health. CGI: Clinical Global Impressions. In: Guy W, Bonato RR, eds. Manual for the ECDEU Assessment Battery, 2, Revised Edition. Chevy Chase, Md: National Institute of Mental Health; 1970:12-1-12-6
41. Fleiss J. Statistical Methods for Rates and Proportions. New York, NY: Wiley & Sons; 1981
42. Hoyt WT. Rater bias in psychological research: when is it a problem and what can we do about it? Psychol Methods 2000;5:64-86
43. Petkova E, Quitkin FM, McGrath PJ, et al. A method to quantify rater bias in antidepressant trials. Neuropsychopharmacology 2000;22: 559-565